Which has better valuation and earnings, TBIO or BFRGW?

Bullfrog AI has lower revenue, but higher earnings than Telesis Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telesis Bio $225.09M 0.00 -$47.72M -$20.52 N/A Bullfrog AI $116.67K N/A N/A N/A N/A

Is TBIO or BFRGW more profitable?

Bullfrog AI has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Company Net Margins Return on Equity Return on Assets Telesis Bio -336.59% N/A -61.89% Bullfrog AI N/A N/A N/A

Which has better earnings and valuation, OABIW or TBIO?

OmniAb has higher earnings, but lower revenue than Telesis Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $38.46M N/A N/A N/A N/A Telesis Bio $225.09M 0.00 -$47.72M -$20.52 N/A

Is OABIW or TBIO more profitable?

OmniAb has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Company Net Margins Return on Equity Return on Assets OmniAb N/A N/A N/A Telesis Bio -336.59% N/A -61.89%

Do analysts prefer TBIO or TMO?

Thermo Fisher Scientific has a consensus price target of $619.41, suggesting a potential upside of 3.81%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Telesis Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Thermo Fisher Scientific 0 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.79

Do analysts rate DHR or TBIO?

Danaher presently has a consensus target price of $228.91, suggesting a potential upside of 11.88%. Given Danaher's stronger consensus rating and higher possible upside, equities research analysts clearly believe Danaher is more favorable than Telesis Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Danaher 0 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.84 Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, DHR or TBIO?

Danaher has higher revenue and earnings than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Danaher $24.57B 5.85 $3.61B $5.63 36.34 Telesis Bio $225.09M 0.00 -$47.72M -$20.52 N/A

Is DHR or TBIO more profitable?

Danaher has a net margin of 15.95% compared to Telesis Bio's net margin of -336.59%. Danaher's return on equity of 11.04% beat Telesis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Danaher 15.95% 11.04% 6.81% Telesis Bio -336.59% N/A -61.89%

Do analysts rate TBIO or A?

Agilent Technologies has a consensus price target of $160.24, suggesting a potential upside of 7.30%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Telesis Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Agilent Technologies 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 2.89

Telesis Bio (TBIO) Competitors

$0.0011 0.00 (0.00%)

As of 08/12/2026

Compare

TBIO vs. BFRGW, OABIW, TMO, DHR, and A

Should you buy Telesis Bio stock or one of its competitors? Telesis Bio's main competitors and comparable companies include Bullfrog AI (BFRGW), OmniAb (OABIW), Thermo Fisher Scientific (TMO), Danaher (DHR), and Agilent Technologies (A). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Telesis Bio compare to Bullfrog AI?

Telesis Bio (NASDAQ:TBIO) and Bullfrog AI (NASDAQ:BFRGW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Bullfrog AI has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
Bullfrog AI	N/A	N/A	N/A

Bullfrog AI has lower revenue, but higher earnings than Telesis Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A
Bullfrog AI	$116.67K	N/A	N/A	N/A	N/A

37.6% of Telesis Bio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Bullfrog AI had 1 more articles in the media than Telesis Bio. MarketBeat recorded 1 mentions for Bullfrog AI and 0 mentions for Telesis Bio. Bullfrog AI's average media sentiment score of 1.89 beat Telesis Bio's score of 0.00 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Telesis Bio	Neutral
Bullfrog AI	Very Positive

Summary

Bullfrog AI beats Telesis Bio on 4 of the 7 factors compared between the two stocks.

How does Telesis Bio compare to OmniAb?

OmniAb (NASDAQ:OABIW) and Telesis Bio (NASDAQ:TBIO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

OmniAb has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
Telesis Bio	-336.59%	N/A	-61.89%

37.6% of Telesis Bio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

OmniAb has higher earnings, but lower revenue than Telesis Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46M	N/A	N/A	N/A	N/A
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A

In the previous week, OmniAb had 1 more articles in the media than Telesis Bio. MarketBeat recorded 1 mentions for OmniAb and 0 mentions for Telesis Bio. OmniAb's average media sentiment score of 1.87 beat Telesis Bio's score of 0.00 indicating that OmniAb is being referred to more favorably in the media.

Company	Overall Sentiment
OmniAb	Very Positive
Telesis Bio	Neutral

Summary

OmniAb beats Telesis Bio on 4 of the 7 factors compared between the two stocks.

How does Telesis Bio compare to Thermo Fisher Scientific?

Telesis Bio (NASDAQ:TBIO) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Thermo Fisher Scientific had 48 more articles in the media than Telesis Bio. MarketBeat recorded 48 mentions for Thermo Fisher Scientific and 0 mentions for Telesis Bio. Thermo Fisher Scientific's average media sentiment score of 1.00 beat Telesis Bio's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Overall Sentiment
Telesis Bio	Neutral
Thermo Fisher Scientific	Positive

Telesis Bio has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

37.6% of Telesis Bio shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Thermo Fisher Scientific has a consensus price target of $619.41, suggesting a potential upside of 3.81%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Telesis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.79

Thermo Fisher Scientific has a net margin of 15.04% compared to Telesis Bio's net margin of -336.59%. Thermo Fisher Scientific's return on equity of 17.09% beat Telesis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
Thermo Fisher Scientific	15.04%	17.09%	8.12%

Thermo Fisher Scientific has higher revenue and earnings than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A
Thermo Fisher Scientific	$46.34B	4.76	$6.70B	$18.59	32.10

Summary

Thermo Fisher Scientific beats Telesis Bio on 15 of the 17 factors compared between the two stocks.

How does Telesis Bio compare to Danaher?

Danaher (NYSE:DHR) and Telesis Bio (NASDAQ:TBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Danaher presently has a consensus target price of $228.91, suggesting a potential upside of 11.88%. Given Danaher's stronger consensus rating and higher possible upside, equities research analysts clearly believe Danaher is more favorable than Telesis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.84
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Danaher had 11 more articles in the media than Telesis Bio. MarketBeat recorded 11 mentions for Danaher and 0 mentions for Telesis Bio. Danaher's average media sentiment score of 1.29 beat Telesis Bio's score of 0.00 indicating that Danaher is being referred to more favorably in the media.

Company	Overall Sentiment
Danaher	Positive
Telesis Bio	Neutral

Danaher has a net margin of 15.95% compared to Telesis Bio's net margin of -336.59%. Danaher's return on equity of 11.04% beat Telesis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	15.95%	11.04%	6.81%
Telesis Bio	-336.59%	N/A	-61.89%

79.1% of Danaher shares are held by institutional investors. Comparatively, 37.6% of Telesis Bio shares are held by institutional investors. 10.8% of Danaher shares are held by company insiders. Comparatively, 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Danaher has higher revenue and earnings than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57B	5.85	$3.61B	$5.63	36.34
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A

Danaher has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

Summary

Danaher beats Telesis Bio on 15 of the 17 factors compared between the two stocks.

How does Telesis Bio compare to Agilent Technologies?

Telesis Bio (NASDAQ:TBIO) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Agilent Technologies had 10 more articles in the media than Telesis Bio. MarketBeat recorded 10 mentions for Agilent Technologies and 0 mentions for Telesis Bio. Agilent Technologies' average media sentiment score of 1.06 beat Telesis Bio's score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Telesis Bio	Neutral
Agilent Technologies	Positive

37.6% of Telesis Bio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Agilent Technologies has a net margin of 19.55% compared to Telesis Bio's net margin of -336.59%. Agilent Technologies' return on equity of 24.33% beat Telesis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
Agilent Technologies	19.55%	24.33%	12.99%

Telesis Bio has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Agilent Technologies has a consensus price target of $160.24, suggesting a potential upside of 7.30%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Telesis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

Agilent Technologies has higher revenue and earnings than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A
Agilent Technologies	$6.95B	6.07	$1.30B	$4.98	29.99

Summary

Agilent Technologies beats Telesis Bio on 14 of the 17 factors compared between the two stocks.

Get Telesis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBIO vs. The Competition

Export

Metric	Telesis Bio	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2K	$9.54B	$7.03B	$13.08B
Dividend Yield	N/A	1.46%	2.58%	10.74%
P/E Ratio	0.00	62.32	269.68	25.26
Price / Sales	0.00	105.53	641.01	104.60
Price / Cash	N/A	26.06	70.59	50.58
Price / Book	0.01	38.59	13.24	6.24
Net Income	-$47.72M	$56.66B	$3.45B	$347.70M
7 Day Performance	N/A	4.04%	2.01%	1.91%
1 Month Performance	N/A	2.60%	1.06%	1.05%
1 Year Performance	N/A	19.62%	67.57%	19.56%

Telesis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBIO Telesis Bio	N/A	$0.00 flat	N/A	N/A	$2K	$225.09M	N/A	200
BFRGW Bullfrog AI	N/A	$0.11 +0.4%	N/A	-73.4%	$0.00	$116.67K	N/A	2	Gap Down
OABIW OmniAb	N/A	$0.08 -5.6%	N/A	-63.3%	$0.00	$28.94M	N/A	106
TMO Thermo Fisher Scientific	4.6397 of 5 stars	$577.21 +2.2%	$619.41 +7.3%	+26.2%	$213.42B	$44.56B	31.05	125,000	Positive News Insider Trade
DHR Danaher	4.493 of 5 stars	$199.52 +2.4%	$228.91 +14.7%	+0.2%	$140.26B	$25.11B	35.44	60,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBIO) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telesis Bio (TBIO) Competitors

TBIO vs. BFRGW, OABIW, TMO, DHR, and A

How does Telesis Bio compare to Bullfrog AI?

Summary

How does Telesis Bio compare to OmniAb?

Summary

How does Telesis Bio compare to Thermo Fisher Scientific?

Summary

How does Telesis Bio compare to Danaher?

Summary

How does Telesis Bio compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBIO vs. The Competition

Telesis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telesis Bio (TBIO) Competitors

TBIO vs. BFRGW, OABIW, TMO, DHR, and A

How does Telesis Bio compare to Bullfrog AI?

Is TBIO or BFRGW more profitable?

Which has better valuation and earnings, TBIO or BFRGW?

Do insiders & institutionals believe in TBIO or BFRGW?

Does the media prefer TBIO or BFRGW?

Summary

How does Telesis Bio compare to OmniAb?

Is OABIW or TBIO more profitable?

Do institutionals and insiders hold more shares of OABIW or TBIO?

Which has better earnings and valuation, OABIW or TBIO?

Does the media prefer OABIW or TBIO?

Summary

How does Telesis Bio compare to Thermo Fisher Scientific?

Does the media prefer TBIO or TMO?

Which has more risk & volatility, TBIO or TMO?

Do insiders & institutionals hold more shares of TBIO or TMO?

Do analysts prefer TBIO or TMO?

Is TBIO or TMO more profitable?

Which has preferable valuation & earnings, TBIO or TMO?

Summary

How does Telesis Bio compare to Danaher?

Do analysts rate DHR or TBIO?

Does the media prefer DHR or TBIO?

Is DHR or TBIO more profitable?

Do insiders and institutionals hold more shares of DHR or TBIO?

Which has preferable earnings & valuation, DHR or TBIO?

Which has more risk & volatility, DHR or TBIO?

Summary

How does Telesis Bio compare to Agilent Technologies?

Does the media prefer TBIO or A?

Do institutionals & insiders hold more shares of TBIO or A?

Is TBIO or A more profitable?

Which has more volatility & risk, TBIO or A?

Do analysts rate TBIO or A?

Which has stronger valuation & earnings, TBIO or A?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBIO vs. The Competition

Telesis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools